Novavax Inc.
Novavax Inc.
01/08/2024 | Press release | Distributed by Public on 01/08/2024 20:34
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
GAITHERSBURG, Md., Aug. 1, 2024/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time(ET) on Thursday, August 8, 2024. Details of the event and replay are as follows:
|
Conference call details: |
|
|
|
|
|
Date: |
August 8, 2024 |
|
|
|
|
Time: |
8:30 a.m. U.S. ET |
|
|
|
|
URL to register phone: |
|
|
|
|
|
Dial-in number: |
(800) 836-8184 (Domestic) or |
|
|
(+1) (646) 357-8785 (International) |
|
|
|
|
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
|
Replay details: |
|
|
|
|
|
Date: |
Available starting at 11:30 a.m. ET, August 8, 2024, until 11:59 p.m. U.S. ET, August 15, 2024 |
|
|
|
|
Dial-in number: |
(888) 660-6345 (Domestic) or |
|
|
(+1) (646) 517-4150 (International) |
|
|
|
|
Passcode: |
52500# |
|
|
|
|
Webcast: |
ir.novavax.com/events, until September 8, 2024 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxfordand Serum Institute of India'sR21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Giovanna Chandler
202-709-5563
[email protected]
SOURCE Novavax, Inc.